1,280 Shares in United Therapeutics Corporation $UTHR Purchased by Inceptionr LLC

Inceptionr LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,280 shares of the biotechnology company’s stock, valued at approximately $368,000.

Several other institutional investors have also recently made changes to their positions in the business. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the second quarter worth approximately $29,000. SVB Wealth LLC bought a new position in shares of United Therapeutics in the first quarter worth about $32,000. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group increased its holdings in United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 98 shares during the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of United Therapeutics in the first quarter worth about $60,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of a number of research reports. Wells Fargo & Company increased their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald increased their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Finally, Bank of America upped their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Price Performance

Shares of UTHR stock opened at $485.97 on Friday. The company has a market cap of $20.92 billion, a P/E ratio of 18.41, a PEG ratio of 4.96 and a beta of 0.77. The stock’s 50-day moving average is $447.65 and its 200 day moving average is $361.75. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the firm earned $6.39 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $486.06, for a total value of $5,346,660.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,877,772.86. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $473.66, for a total transaction of $10,657,350.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 578,435 shares of company stock worth $252,731,147 over the last ninety days. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.